Silhouette

Rolf M Huseby

Apoimmune, Inc.

Employers

Affiliated Awards

Award Title Agency Phase Award amount Start Date End Date
ApoFasL: a Novel Immunotherapeutic for T1D
Apoimmune, Inc.
Principal Investigator
HHS 1 $422K 08/06/07 01/31/09
Chimeric CD80-SA as a Novel Cancer Vaccine
Apoimmune, Inc.
Principal Investigator
HHS 1 $417K 09/01/06 08/31/07
Chimeric CD80-SA as a Novel Cancer Vaccine
Apoimmune, Inc.
Principal Investigator
HHS 1 $352K 09/27/05 08/31/06